Skip to main content

Table 4 Predictors of adherence

From: Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

Variable

Main analysis set

Completer population

Point estimate

p-value

Point estimate

p-value

Treatment: OROS MPH 54 mg

−1.0472

0.0221

−0.0645

0.7712

Treatment: OROS MPH 72 mg

−0.9122

0.0371

−0.2533

0.2244

Sex (Male)

0.6374

0.0892

Country

a

NS

b

b

DUSI: psychiatric disorder

−0.0296

0.0252

DUSI health status

−0.0238

0.0563

−0.0182

0.0012

Education level: primary

0.1759

0.8102

0.9829

0.0107

Education level: secondary

0.4870

0.2963

0.1399

0.5012

Education level: high school

1.0683

0.0284

1.2055

< 0.0001

Time since ADHD diagnosis

0.0770

0.0070

  1. a Point estimates for individual countries ranged from −0.4944 to +2.6307; none were statistically significant.
  2. b Point estimates for individual countries ranged from −2.1366 to +3.2225; values were statistically significant for France (point estimate: −2.1366 [p < 0.0001]) and Sweden (estimate: −1.4175 [p = 0.0074]).